GLP-RT
Triple Receptor Agonist
Dosage
10mg / 15mg / 20mg
Unit Size
1 Vial
// Add to Cart
GLP-RT10
$90.00
26 in stock
GLP-RT15
$100.00
14 in stock
GLP-RT20
$120.00
20 in stock
GLP-RT30
$140.00
98 in stock
GLP-RT60
$200.00
99 in stock
What is GLP-RT?
GLP-RT (Retatrutide) is a next-generation, once-weekly injectable peptide that simultaneously activates three key metabolic receptors: GIP, GLP-1, and glucagon. This triple agonist approach represents one of the most advanced metabolic peptides currently under clinical investigation, demonstrating up to 24% body weight reduction in Phase 2 trials — among the highest recorded for any compound in its class.
3
Receptor Targets
Up to 24%
Weight Reduction (Phase 2)
1×/week
Dosing Frequency
Key Benefits
Fat Loss
Triple receptor activation produces synergistic reductions in body fat, particularly visceral adipose tissue.
Appetite Suppression
GLP-1 agonism suppresses appetite and slows gastric emptying, reducing caloric intake naturally.
Insulin Sensitivity
Improves glucose regulation and insulin sensitivity through GIP receptor activation and pancreatic beta-cell support.
Energy Expenditure
Glucagon receptor activation increases hepatic fat breakdown and total energy expenditure.
Cardiovascular Risk Reduction
Phase 2 data showed improvements in blood pressure, lipids, and other cardiovascular risk markers alongside weight loss.
Metabolic Flexibility
Promotes fat as a primary fuel source while preserving lean mass, improving overall metabolic health profiles.
How It Works
GLP-1 Receptor Activation
Stimulates GLP-1 receptors in the gut and brain to suppress appetite, slow gastric emptying, and improve insulin secretion in response to meals.
GIP Receptor Activation
Activates glucose-dependent insulinotropic polypeptide receptors, enhancing insulin response and promoting fat metabolism at the adipose tissue level.
Glucagon Receptor Activation
Engages glucagon receptors in the liver to increase fat breakdown, gluconeogenesis suppression, and total energy expenditure.
Synergistic Metabolic Effect
The simultaneous activation of all three receptors produces effects greater than any single agonist alone, explaining its exceptional clinical weight loss results.
Common Protocol (Research Reference)
1–12 mg
Dose (titrating)
1×/week
Frequency
24 wks
Typical cycle length
Research Use Notice
GLP-RT is a research peptide not approved by the FDA for human use. This information is for educational purposes only. Always consult a qualified healthcare professional before considering any peptide protocol.